Catherine Willett, Jessica Caverly Rae, Katy O Goyak, Gary Minsavage, Carl Westmoreland, Melvin Andersen, Mark Avigan, Daniel Duché, Georgina Harris, Thomas Hartung, Hartmut Jaeschke, Andre Kleensang, Brigitte Landesmann, Suzanne Martos, Marilyn Matevia, Colleen Toole, Andrew Rowan, Terry Schultz, Jennifer Seed, John Senior, Imran Shah, Kalyanasundaram Subramanian, Mathieu Vinken, Paul Watkins
{"title":"Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.","authors":"Catherine Willett, Jessica Caverly Rae, Katy O Goyak, Gary Minsavage, Carl Westmoreland, Melvin Andersen, Mark Avigan, Daniel Duché, Georgina Harris, Thomas Hartung, Hartmut Jaeschke, Andre Kleensang, Brigitte Landesmann, Suzanne Martos, Marilyn Matevia, Colleen Toole, Andrew Rowan, Terry Schultz, Jennifer Seed, John Senior, Imran Shah, Kalyanasundaram Subramanian, Mathieu Vinken, Paul Watkins","doi":"10.14573/altex.1401281","DOIUrl":null,"url":null,"abstract":"<p><p>A workshop sponsored by the Human Toxicology Project Consortium (HTPC), \"Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action\" brought together experts from a wide range of perspectives to inform the process of pathway development and to advance two prototype pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and steatosis. The first half of the workshop focused on the theory and practice of pathway development; the second on liver disease and the two prototype pathways. Participants agreed pathway development is extremely useful for organizing information and found that focusing the theoretical discussion on a specific AOP is extremely helpful. In addition, it is important to include several perspectives during pathway development, including information specialists, pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure the biology is well captured and end use is considered.</p>","PeriodicalId":520550,"journal":{"name":"ALTEX","volume":" ","pages":"500-19"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779550/pdf/nihms-763117.pdf","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ALTEX","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14573/altex.1401281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16
Abstract
A workshop sponsored by the Human Toxicology Project Consortium (HTPC), "Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action" brought together experts from a wide range of perspectives to inform the process of pathway development and to advance two prototype pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and steatosis. The first half of the workshop focused on the theory and practice of pathway development; the second on liver disease and the two prototype pathways. Participants agreed pathway development is extremely useful for organizing information and found that focusing the theoretical discussion on a specific AOP is extremely helpful. In addition, it is important to include several perspectives during pathway development, including information specialists, pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure the biology is well captured and end use is considered.